FDA approves Lerochol autoinjector and updates indication for monthly PCSK9 therapy

The new device gives adults with hypercholesterolaemia an additional self-administration option for once-monthly Lerochol, while updated prescribing information reflects evidence linking LDL-C reduction with lower cardiovascular event risk.

The US Food and Drug Administration (FDA) has approved an autoinjector version of Lerochol (lerodalcibep-liga) 300 mg/1.2 mL and updated the indication statement for the PCSK9 inhibitor, which is used alongside diet and exercise to reduce LDL-C in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH).

The autoinjector adds a single-use administration option to the existing pre-filled syringe and is expected to become available in the US by January 2027, although approval does not itself establish insurance coverage.

Field	Content
Alert Type	Drug Approval
Drug Name	Lerochol (lerodalcibep-liga)
Indication	As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH). The updated prescribing information also states that cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk of major adverse cardiovascular events in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors added to statin therapy. (Business Wire)
Therapy Area(s)	Cardiovascular disease; Lipid management
Geography	United States (FDA)
What Happened	On 17 August 2026, the FDA approved a single-use autoinjector for Lerochol (lerodalcibep-liga) 300 mg/1.2 mL, providing an additional delivery option alongside the already available pre-filled syringe. Lerochol is administered subcutaneously once monthly. The FDA also approved an update to the indication statement reflecting evidence that LDL-C reduction lowers major adverse cardiovascular event risk in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors added to statin therapy. Lerochol itself was originally FDA approved on 12 December 2025 for LDL-C reduction in adults with hypercholesterolaemia, including HeFH. (Business Wire)
Why It Matters	PCSK9-directed therapy can require long-term treatment, making administration and treatment burden relevant considerations for patients and prescribers. The pressure-activated autoinjector delivers the monthly dose in seconds and provides another self-administration option without replacing the existing pre-filled syringe. Lerochol can also be stored at room temperature for up to 90 days, which may offer additional practical flexibility, although the effect of the new device on adherence has not been established. (Business Wire)
Supporting Context	Lerochol is a third-generation PCSK9 inhibitor comprising an engineered PCSK9-binding adnectin fused to human serum albumin to extend its plasma half-life. Its original FDA approval was supported by trials including adults with atherosclerotic cardiovascular disease or increased cardiovascular risk and patients with HeFH. (Business Wire)
Key Takeaway	FDA approval of the Lerochol autoinjector gives eligible patients another way to self-administer their once-monthly PCSK9 therapy while retaining the existing pre-filled syringe option.
What to Watch	LIB Therapeutics expects to make the autoinjector available in the US by January 2027, with a direct-to-patient cash price of $199 per month, matching the existing pre-filled syringe programme. The company expects insurance coverage to expand gradually during 2027, but reimbursement is separate from FDA approval. (Business Wire)
Primary Source	LIB Therapeutics FDA approval announcement
Relevant Date	17 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com